Skip to main content

Iqvia Holdings Inc(IQV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low174.76
Day High179.72
Open:178.33
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
StockStory
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
AAON
Tipranks
IQVIA Holdings (IQV) Gets a Buy from RBC Capital
StockStory
Reflecting On Drug Development Inputs & Services Stocks’ Q4 Earnings: IQVIA (NYSE:IQV)
IQV
Tipranks
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), IQVIA Holdings (IQV) and Xenon (XENE)
StockStory
3 Profitable Stocks with Questionable Fundamentals
QRVO
StockStory
3 Value Stocks We Steer Clear Of
LH
StockStory
3 Mid-Cap Stocks We Keep Off Our Radar
ACM
StockStory
1 S&P 500 Stock Worth Your Attention and 2 We Question
KO
Tipranks
Analysts Are Bullish on These Healthcare Stocks: IQVIA Holdings (IQV), Roche Holding AG (RHHVF)
Tipranks
IQVIA Holdings (IQV) Gets a Hold from Citi
Tipranks
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), RxSight (RXST) and Cardiff Oncology (CRDF)
StockStory
3 Reasons to Sell IQV and 1 Stock to Buy Instead
IQV
StockStory
1 Healthcare Stock to Consider Right Now and 2 We Turn Down
GEHC
StockStory
Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories Shares Plummet, What You Need To Know
IART
Tipranks
Truist Financial Sticks to Its Buy Rating for IQVIA Holdings (IQV)
Zacks Investment Research
TransUnion Stock Gains 6% Post Reporting Q4 Earnings & Revenue Beat
TransUnion Stock Gains 6% Post Reporting Q4 Earnings & Revenue Beat
Zacks Investment Research
Waste Connections Stock Slides 7% Since Q4 Earnings Beat Estimates
Waste Connections Stock Slides 7% Since Q4 Earnings Beat Estimates
StockStory
The Top 5 Analyst Questions From IQVIA’s Q4 Earnings Call
IQV
Tipranks
IQVIA Holdings Earnings Call Signals AI-Driven Growth
Tipranks
Jefferies Reaffirms Their Buy Rating on IQVIA Holdings (IQV)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: IQVIA Holdings (IQV) and Molina Healthcare (MOH)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Qiagen (QGEN) and Ligand Pharma (LGND)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Ocular Therapeutix (OCUL) and Arrowhead Pharmaceuticals (ARWR)
Tipranks
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Haemonetics (HAE) and Denali Therapeutics (DNLI)
Tipranks
Barclays Keeps Their Hold Rating on IQVIA Holdings (IQV)
Tipranks
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Omnicell (OMCL) and MiMedx Group (MDXG)
StockStory
IQV Q4 Deep Dive: Market Cautions Despite Revenue Beat and AI Strategy Emphasis
IQV
Zacks Investment Research
IQVIA Q4 Earnings & Revenues Beat Estimates, Increase Y/Y
IQVIA Q4 Earnings & Revenues Beat Estimates, Increase Y/Y
Motley Fool
IQVIA (IQV) Q4 2025 Earnings Call Transcript
StockStory
IQVIA (IQV) Stock Trades Down, Here Is Why
IQV
StockStory
IQVIA’s (NYSE:IQV) Q4 CY2025 Sales Top Estimates
IQV
StockStory
IQVIA (IQV) Reports Q4: Everything You Need To Know Ahead Of Earnings
IQV

Profile

IQVIA Holdings Inc. provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company was formed through the merger of IMS Health (RX) and Quintiles. The company is focused on helping healthcare clients to better serve patients by bringing in updated and innovative ideas in the process of clinical development and commercialization, speed innovation and accelerate improvements. I

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.